Malaysian Healthy Ageing Society Chew Boon How 1* MMed (FamMed) , - - PowerPoint PPT Presentation

malaysian healthy ageing society
SMART_READER_LITE
LIVE PREVIEW

Malaysian Healthy Ageing Society Chew Boon How 1* MMed (FamMed) , - - PowerPoint PPT Presentation

Organised by: Co-Sponsored: Malaysian Healthy Ageing Society Chew Boon How 1* MMed (FamMed) , Sazlina Shariff-Ghazali 1 MMed (FamMed) , Zaiton Ahmad 1 MMed (FamMed) , Mastura Ismail 2 MMed (FamMed) , Jamaiyah Haniff 3 (MPH) , Mustapha Feisul


slide-1
SLIDE 1 Organised by: Malaysian Healthy Ageing Society Co-Sponsored:
slide-2
SLIDE 2
slide-3
SLIDE 3

Chew Boon How1*MMed (FamMed), Sazlina Shariff-Ghazali 1MMed (FamMed), Zaiton Ahmad1MMed (FamMed), Mastura Ismail2MMed (FamMed), Jamaiyah Haniff3(MPH), Mustapha Feisul Idzwan4(MPH), Mohd Adam Bujang3(Bsc Statistic)

1Department of Family Medicine, Universiti Putra Malaysia, 2Klinik Kesihatan Seremban 2, Negeri Sembilan, 3Clinical

Research Centre, Hospital Kuala Lumpur,4Disease Control Division, Ministry of Health Malaysia, Putrajaya.

slide-4
SLIDE 4
  • Age has long been recognised as a significant

factor for health.1 2

  • Many cardiovascular disease risk scoring

systems give larger weightage or marks for the older age groups.

  • 1. de Craen AJ et al. Tijdschr Gerontol Geriatr 2009;40(6):237-43.
  • 2. Jaakko T. Cardiovascular Risk Through The Ages, Proceedings of the Future Forum Conference held in Noordwijk, The
Netherlands, October 2003 2004;5(2):9-17.
slide-5
SLIDE 5
  • Children of long-living parents, suggesting

that they had advantageous cardiovascular risk profiles

 (the Leiden research program on ageing and

Framingham offspring study.)1 6

  • The association of ageing and many

cardiometabolic diseases were degenerative processes leading to cellular apoptosis beyond regeneration or repairs.5

  • 1. de Craen AJ et al. Tijdschr Gerontol Geriatr 2009;40(6):237-43.
  • 5. Navarro A et al. American Journal of Physiology - Cell Physiology 2007;292(2):C670-C86.
  • 6. Terry DF et al. Archives of Internal Medicine 2007;167(5):438-44.
slide-6
SLIDE 6
  • Cardiometabolic diseases cause premature

ageing and death.7

  • Vascular ageing and remodelling 9
  • Many studies had reported positive relationship
  • f disease control (glycaemic, blood pressure and

lipid) in T2D and diabetes-related complications and death, but the evidence was inconclusive and even against intensive control in the older group

  • f patients.8
  • 7. Girndt M et al. Biomarkers of Ageing: from Molecular Biology to Clinical Perspectives 2010;45(10):797-800.
  • 8. Huang ES et al. Diabetes Care 2011;34(6):1329-36.
  • 9. Bachschmid MM et al. Annals of Medicine 2012:1-20.
slide-7
SLIDE 7
  • We examined the independent effect of age

≥ 60 years on disease control and its relationship with diabetes-related complications.

slide-8
SLIDE 8
  • Adult Diabetes Control and Management (

) public health centres (289 health clinics, hospitals) patients ( patients were from hospital) health clinics hospitals (8 states and 2 federal territories) of 15 states and federal territories in Malaysia.

8
slide-9
SLIDE 9
  • The proportion of T2D patients notified in this

database as compared to the estimated total T2D patients in these states and federal territories was .

  • Only adult patients (

).

  • All patients were
  • f the on-going

registry and given the opportunity to .

  • Participation in ADCM was non-mandatory for

patients and health centres.

9
slide-10
SLIDE 10
  • Registrations at local centers were generally

performed by trained physicians, assistant physicians and nurses. , developed and maintained by Clinical Research Centre (CRC), Ministry of Health, Malaysia.

10
slide-11
SLIDE 11
slide-12
SLIDE 12
slide-13
SLIDE 13
slide-14
SLIDE 14
  • The

was as when their case record fulfilled all these criteria:

 (i) either

  • r

 (ii) those whose current

.

14
slide-15
SLIDE 15
  • Comparisons were performed regarding mean

levels by use of the Student’s t test for unpaired samples and regarding proportions by use of the Chi square test/Fisher Exact’s Test. as dependent variables and with indentified significant registered variables as mentioned above as independent variables.

  • A P value < 0.05 was considered to be significant
15
slide-16
SLIDE 16

Result

was female.

  • Malay consisted of

, Chinese and Indian .

slide-17
SLIDE 17 < 60 years, n (%) ≥ 60 years, n (%) χ2 or t Statistic p Age, mean (SD) 50.22 (7.19) 68.12 (6.54) 343.50 <0.0001 Gender Male 15150 (39.0) 13789 (43.0) 112.76 <0.0001 Female 23584 (60.8) 18257 (56.9) Missing 66 (0.2) 43(0.1) Total 38800 (100.0) (54.7)* 32089 (100.0) (45.3)* Ethnicity Malay 25942 (66.9) 17960 (56.0) 2397.60 <0.0001 Chinese 4823 (12.4) 8628 (26.9) Indian 7555 (19.5) 5184 (16.2) Other Malaysians 351 (0.9) 237 (0.7) Foreigner 65 (0.2) 23 (0.1) Missing 64 (0.2) 57 (0.2) Total 38800 (100.0) (54.7)* 32089 (100.0) (45.3)* Diabetes Duration in year, mean (SD) 4.84 (4.53) 7.12 (6.39) 49.81 <0.0001 <5 18467 (47.6) 10717 (33.4) 2077.02 <0.0001 5-9 9618 (24.8) 8896 (27.7) >=10 3693 (9.5) 6071 (18.9) Missing 7022 (18.1) 6405 (20.0) Total 38800 (100.0) (54.7)* 32089 (100.0) (45.3)*
slide-18
SLIDE 18

< 60 years, n (%) ≥ 60 years, n (%) χ2 or t Statistic p

BMI, mean (SD) 28.22 (5.69) 26.10 (6.07)
  • 41.74
<0.0001 BMI < 23 12629 (32.5) 14072 (43.9) 955.88 <0.0001 BMI ≥ 23 26171 (67.5) 18017 (56.1) Total 38800 (100.0) (54.7)* 32089 (100.0) (45.3)* Systolic BP, mean (SD) 134.21 (18.46) 139.86 (20.35) 34.57 <0.0001 Diastolic BP, mean (SD) 80.36 (10.23) 76.78 (10.81)
  • 40.38
<0.0001 BP ≥ 130/80 mmHg 23544 (75.2) 19679 (78.2) 70.60 <0.0001 BP < 130/80 mmHg 7784 (24.8) 5496 (21.8) Total 31328 (100.0) (55.4)* 25175 (100.0) (44.6)* HbA1c, mean (SD) 8.68 (2.28) 7.94 (2.02)
  • 32.85
<0.0001 HbA1c ≥ 6.5% 17487 (85.5) 13022 (77.4) 410.04 <0.0001 HbA1c < 6.5% 2956 (14.5) 3798 (22.6) Total 20443 (100.0) (54.9)* 16820 (100.0) (45.1)* LDL-C, mean (SD) 3.24 (1.11) 3.12 (1.08)
  • 11.10
<0.0001 LDL-C> 2.6 15462 (71.5) 11337 (65.8) 75.54 <0.0001 LDL-C≤ 2.6 6164 (28.5) 5885 (34.2) Total 21626 (100.0) (55.7)* 17222 (100.0) (44.3)* HDL-C, mean (SD) 1.28 (0.52) 1.32 (0.52) 7.05 <0.0001 HDL-C< 1.1 7527 (34.4) 5258 (30.2) 99.98 <0.0001 HDL-C≥ 1.1 14348 (65.6) 12144 (69.8) Total 21875 (100.0) (55.7)* 17402 (100.0) (44.3)* TG, mean (SD) 2.02 (1.33) 1.83 (1.12)
  • 15.90
<0.0001 TG> 1.7 11940 (47.0) 8380 (41.2) 151.55 <0.0001 TG≤ 1.7 13461 (53.0) 11936 (58.8) Total 25401 (100.0) (55.6)* 20316 (100.0) (44.4)*
slide-19
SLIDE 19 B SE Wald df p value OR* 95% C.I. for OR Nagelkerke R2 Lower Upper HbA1c ≤ 6.5% (1), n= 37263 ≥ 60 years 0.58 0.03 420.97 1 <0.0001 1.79 1.70 1.90 0.04 Blood Pressure < 130/80 mmHg (1), n= 56503 ≥ 60 years
  • 0.24
0.02 126.41 1 <0.0001 0.80 0.76 0.82 0.02 LDL-C ≤ 2.6 mmol/L (1), n= 38848 ≥ 60 years 0.14 0.02 37.74 1 <0.0001 1.15 1.10 1.21 0.03 HDL-C ≥ 1.1 mmol/L (1), n= 39277 ≥ 60 years 0.19 0.02 64.60 1 <0.0001 1.21 1.15 1.26 0.08 TG ≤ 1.7 mmol/L (1), n= 45717 ≥ 60 years 0.18 0.02 83.56 1 <0.0001 1.20 1.15 1.25 0.02
slide-20
SLIDE 20
slide-21
SLIDE 21
slide-22
SLIDE 22 B SE Wald df p value OR* 95% C.I. for OR Nagelker ke R2 Lower Upper Any Diabetes Complications (1), n= 53393 ≥ 60 years 0.30 0.02 162.33 1 <0.0001 1.35 1.29 1.41 0.10 Macrovascular Complications (stroke or IHD) (1), n= 53393 ≥ 60 years 0.66 0.04 233.57 1 <0.0001 1.94 1.78 2.11 0.16 Stroke (1), n= 41421 ≥ 60 years 0.58 0.09 39.99 1 <0.0001 1.79 1.49 2.14 0.12 IHD (1), n= 38768 ≥ 60 years 0.68 0.05 197.84 1 <0.0001 1.97 1.79 2.16 0.18
slide-23
SLIDE 23 B SE Wald df p value OR* 95% C.I. for OR Nagelker ke R2 Lower Upper Microvascular Complications (retinopathy or nephropathy or foot problem) (1), n= 53393 ≥ 60 years 0.20 0.03 62.92 1 <0.0001 1.22 1.16 1.28 0.08 Retinopathy (1), n= 32663 ≥ 60 years 0.32 0.04 63.20 1 <0.0001 1.38 1.27 1.49 0.09 Nephropathy (1), n= 39161 ≥ 60 years 0.11 0.03 11.41 1 0.001 1.12 1.05 1.19 0.10 Diabetes Foot Problems (1), n= 42755 ≥ 60 years 0.26 0.04 35.27 1 <0.0001 1.30 1.19 1.41 0.04
slide-24
SLIDE 24

Discussion- Risk Control & Age

  • The proportion of our older patients achieving

HbA1c and LDL-C targets were comparable to the Asian countries (Hong Kong, India, Korea, Philippines, Singapore, Taiwan, and Thailand) in the (Joint Asia Diabetes Evaluation) program (35.3% achieved HbA1c < 7% and 34% achieved LDL-C < 2.6 mmol/L).26

  • 26. So W-Y et al. Journal of Diabetes 2011;3(2):109-18.
slide-25
SLIDE 25

Discussion- Age & Risk

  • The attenuated association between

cardiometabolic risk markers and older people was also reported in United States and these Asian countries.25 26

  • Inverse relationship of glycaemic control

(HbA1c ≤ 7.5%) and age among the T2D patients was also reported in a primary care setting in UK.27

  • 25. Janssen I. Nutr Metab Cardiovasc Dis. 2009;19(3):163-69.
  • 26. So W-Y et al. Journal of Diabetes 2011;3(2):109-18.
  • 27. Nagrebetsky A et al. Diabetes Res Clin Pract. 2012 Jan 17.
slide-26
SLIDE 26

Discussion-Risk & Complication

  • Despite good control of most cardiovascular risk

factors, the elderly patients with T2D were still suffering from all types of diabetes complications.

  • Improving diseases control and increasing

complications were observed in French elderly T2D.30

  • In a 15-years follow-up Chinese Multi-provincial

study, diabetes and older age (≥ 45 years) were predictors of coronary heart disease and ischaemic stroke despite well controlled LDL-C.31

  • 30. Pornet C et al. Diabetes Metab 2011;37(2):152-61.
  • 31. Liu J et al. Diabetes Res Clin Pract. 2012 Jan 11. [Epub ahead of print]
slide-27
SLIDE 27

Limitations

  • Missing data/unknown status for many

complications

  • Representativeness
  • Not generalizable to east Malaysia
  • Could not ascertain the sequence of events

between onset of the diabetes-related complications and diseases control

  • Unobservable confounders may still exist and bias

the results as evidenced by the modest effect of the models

slide-28
SLIDE 28

Conclusions

  • 1. Age ≥ 60 years was an independent risk factor

for diabetes-related complications despite good control of cardiovascular risk factors.

  • 2. Diabetes in the older patients could be a

significant cause of morbidity in this country.

  • 3. It was very likely that good diseases control

were only achieved after the onset of complications.

slide-29
SLIDE 29
  • 4. Caution on the current recommended clinical

targets control in these patients who were already having more longstanding diseases and complications.48

  • 5. The goals of therapy have to be safe and more

holistic diabetes care including having quality

  • f life as one of the aims of treatment for

elderly T2D.

  • 48. Boussageon R et al. BMJ 2011;343:d4169.
slide-30
SLIDE 30

The End